Phase 0 Study to Define the Effect of Low Dose Ethacrynic Acid on Total Glutathione (GSH) Levels and Glutathione S-transferase (GST) Activity (TRACer)

November 10, 2026 updated by: Randall F Holcombe, University of Vermont Medical Center

This study will examine how low doses of ethacrynic acid affect substances in the blood involved in protecting cells from damage. These substances include glutathione and an enzyme called glutathione S-transferase. The findings may help researchers plan future cancer studies.

Ethacrynic acid is an approved prescription medicine used to treat fluid buildup. Its use in this study to change these blood markers in healthy adults is experimental.

Up to 40 healthy adults will participate. The first group will receive a 25 mg oral dose at each of two visits approximately one week apart. If results meet the study criteria, a second group will receive 12.5 mg at each visit.

Participants will provide blood samples before and approximately 90 minutes after each dose. Study staff will ask about symptoms during the visits and during a final telephone call approximately one week after the second dose. Participation will last approximately two weeks.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Glutathione (GSH) and glutathione S-transferases (GSTs) contribute to cellular protection against oxidative stress and the detoxification of electrophilic compounds. In cancer cells, increased activity of these systems may contribute to resistance to anticancer therapies. Ethacrynic acid, an approved loop diuretic, can inhibit GST activity and react with GSH to form conjugates, potentially reducing cellular GSH availability. Whether low oral doses produce measurable pharmacodynamic effects in healthy adults remains uncertain.

TRACer will investigate these biological effects in healthy volunteers to reduce confounding from malignancy, prior cancer treatment, organ dysfunction, and concurrent prescription medications. The study uses paired measurements before and after drug administration, allowing each participant to serve as their own control. Repeating administration approximately one week later will help characterize the consistency of the pharmacodynamic response. Comparison of pre-dose measurements across visits will also provide information about whether changes persist between administrations.

The sequential cohort design evaluates the higher dose first. Enrollment into the lower-dose cohort will occur only if the initial cohort meets the protocol-specified criterion for biological activity. This approach is intended to determine whether target engagement can be demonstrated at doses below those commonly used to produce diuresis.

Peripheral blood mononuclear cells provide accessible material for assessing GST activity. Measurements of total GSH in plasma and erythrocytes provide complementary information about glutathione pools in different blood compartments. Coded specimens will undergo research laboratory analysis at the University of Vermont. These assays will not guide clinical care, and individual research results will not be returned to participants.

The study is intended to inform the design of subsequent investigations of ethacrynic acid as a potential adjunct to cancer therapy. It does not evaluate antitumor activity, and no direct clinical benefit to participants is anticipated.

Study Type

Interventional

Enrollment (Estimated)

40

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy volunteer without acute or chronic illness.
  • Age 18 years or older.
  • Willing and able to provide informed consent.

Exclusion Criteria:

  • Ongoing use of any prescription medication.
  • Known hypersensitivity to ethacrynic acid.
  • Known renal or hepatic impairment.
  • Current pregnancy or breastfeeding.
  • Current tinnitus, hearing impairment, or other significant hearing disorder.
  • Baseline systolic blood pressure of 100 mm Hg or less.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Ethacrynic Acid 25 mg

Approximately 20 participants will receive ethacrynic acid 25 mg orally at each of two dosing visits separated by one week ±1 day.

Oral ethacrynic acid administered at 25 mg or 12.5 mg per dose, according to cohort, on two occasions approximately one week apart.

Other Names:
  • Edecrin
Experimental: Ethacrynic Acid 12.5 mg

If the first cohort meets the protocol-specified biological activity criterion, approximately 20 additional participants will receive ethacrynic acid 12.5 mg orally at each of two dosing visits separated by one week ±1 day.

Oral ethacrynic acid administered at 25 mg or 12.5 mg per dose, according to cohort, on two occasions approximately one week apart.

Other Names:
  • Edecrin

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Peripheral Blood Mononuclear Cell GST Activity
Time Frame: Before dosing and 90 ±15 minutes after dosing at the first visit and the second visit approximately one week later

Change in glutathione S-transferase activity from the pre-dose measurement to the post-dose measurement, evaluated separately for each dosing visit.

Before dosing and 90 ±15 minutes after dosing at the first visit and the second visit approximately one week later

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Plasma Total Glutathione
Time Frame: Before dosing and 90 ±15 minutes after dosing at both dosing visits

Change in plasma total glutathione from the pre-dose measurement to the post-dose measurement, evaluated separately for each dosing visit.

Before dosing and 90 ±15 minutes after dosing at both dosing visits
Change in Erythrocyte Total Glutathione
Time Frame: Before dosing and 90 ±15 minutes after dosing at both dosing visits

Change in erythrocyte total glutathione from the pre-dose measurement to the post-dose measurement, evaluated separately for each dosing visit.

Before dosing and 90 ±15 minutes after dosing at both dosing visits
Number of Participants With Adverse Events
Time Frame: From the first dosing visit through the final telephone assessment, one week ±2 days after the second dosing visit, approximately two weeks

Number of participants experiencing adverse events, summarized by event type, severity, and relatedness. Severity will be graded using the protocol's CTCAE criteria.

From the first dosing visit through the final telephone assessment, one week ±2 days after the second dosing visit, approximately two weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2029

Primary Completion (Estimated)

January 1, 2029

Study Completion (Estimated)

January 1, 2029

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • UVMCC2609

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.